|
Balance Sheet Cash Flow Statement 3180 Porter Dr. Palo Alto, CA 94304 CA Tel. 650-496-3777 Fax 650-496-3781 |
Type: Public
On the web:
http://www.jazzpharmaceuticals.com
Employees:
216
Employee growth: (47.2%)
Jazz Pharmaceuticals wants to paint the town with successful treatments for niche psychiatric and neurological conditions. The company has several products on the market, including narcolepsy treatment Xyrem (which is also in clinical trials for the treatment of fibromyalgia) and Antizol, an antidote for ethylene glycol and methanol poisoning. The company acquired both drugs through its 2005 purchase of Orphan Medical. Jazz Pharmaceuticals also has US marketing rights for Solvay Pharmaceuticals' Luvox CR, a treatment for obsessive compulsive disorder (OCD) and social anxiety disorder that the FDA approved in 2008.
Key numbers for fiscal year ending December, 2008:
Sales: $67.5M
One year growth: 3.4%
Net income: ($184.3)M
Officers:
Executive Chairman and CEO: Bruce C. Cozadd
President: Robert M. (Bob) Myers
SVP and CFO: Kathryn E. Falberg
Competitors:
Cephalon
GlaxoSmithKline
Pfizer
